Recurrent high-grade glioma treated with bevacizumab: Prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival

Journal of Neuro-Oncology

Volumn 115, Issue 2, 2013, Pages 267-276

  Chen, Christina ^a   Huang, Raymond ^a,b   MacLean, Ainsley ^c   Muzikansky, Alona ^d   Mukundan, Srinivasan ^a,b   Wen, Patrick Y ^a,b,e   Norden, Andrew D ^a,b,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Anti angiogenic therapy; Bevacizumab; High grade glioma; MRI biomarkers; Tissue biomarkers

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; PANOBINOSTAT; TEMOZOLOMIDE;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DISEASE PROGRESSION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84886581973     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1225-0     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10-29
2. CBTRUS (2012). Statistical report: primary brain tumors in the United States, 2004-2008. Published by the Central Brain Tumor Registry of the United States
3. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
4. Carson KA, Grossman SA, Fisher JD, Shaw EG (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25(18):2601-2606
5. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740
6. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740-745
7. Pope WB, Young JR, Ellingson BM (2011) Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 11(3):336-344
8. Sathornsumetee S, Cao Y, Marcello JE et al (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26(2):271-278
9. Pope WB, Qiao XJ, Kim HJ et al (2012) Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 108(3):491-498
10. Sawlani RN, Raizer J, Horowitz SW et al (2010) Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology 255(2):622-628
11. Najafi M, Soltanian-Zadeh H, Jafari-Khouzani K, Scarpace L, Mikkelsen T (2012) Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI. PLoS One 7(1):e29945
12. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280
13. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963-1972
14. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59(4):793-797
15. Dorenbeck U, Grunwald IQ, Schlaier J, Feuerbach S (2005) Diffusion-weighted imaging with calculated apparent diffusion coefficient of enhancing extra-axial masses. J neuroimaging 15(4):341-347
16. Guo AC, Cummings TJ, Dash RC, Provenzale JM (2002) Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 224(1):177-183
17. Rumboldt Z, Camacho DL, Lake D, Welsh CT, Castillo M (2006) Apparent diffusion coefficients for differentiation of cerebellar tumors in children. AJNR Am J Neuroradiol 27(6):1362-1369
18. Yamasaki F, Kurisu K, Satoh K et al (2005) Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 235(3):985-991
19. Higano S, Yun X, Kumabe T et al (2006) Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 241(3):839-846
20. Kitis O, Altay H, Calli C, Yunten N, Akalin T, Yurtseven T (2005) Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J Radiol 55(3):393-400
21. Murakami R, Hirai T, Sugahara T et al (2009) Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one-versus two-parameter pilot method. Radiology 251(3):838-845
22. Sugahara T, Korogi Y, Kochi M et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9(1):53-60
23. Crawford FW, Khayal IS, McGue C et al (2009) Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol 91(3):337-351
24. Saraswathy S, Crawford FW, Lamborn KR et al (2009) Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 91(1):69-81
25. Pope WB, Kim HJ, Huo J et al (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252(1):182-189
26. Jain R, Scarpace LM, Ellika S et al (2010) Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 96(3):423-431
27. Mong S, Ellingson BM, Nghiemphu PL et al (2012) Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol 33(9):1763-1770
28. Gerstner ER, Frosch MP, Batchelor TT (2010) Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 28(6):e91-e93
29. Rieger J, Bahr O, Muller K, Franz K, Steinbach J, Hattingen E (2010) Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 99(1):49-56
30. Gorlia T, Stupp R, Brandes AA et al (2012) New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 48(8):1176-1184
31. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1):83-95
32. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8):1258-1260
33. Prados M, Cloughesy T, Samant M et al (2011) Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13(1):143-151
34. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779-787
35. Gallego Perez-Larraya J, Lahutte M, Petrirena G et al (2012) Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST+F criteria. Neuro Oncol 14(5):667-673
36. Kamoun WS, Ley CD, Farrar CT et al (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27(15):2542-2552